Mode of death in heart failure: findings from the ATLAS trial
暂无分享,去创建一个
[1] P. Poole‐Wilson,et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. , 2001, Archives of internal medicine.
[2] J. Cleland,et al. Clinical trials update: IMPROVEMENT‐HF, COPERNICUS, MUSTIC, ASPECT‐II, APRICOT and HEART , 2000, European journal of heart failure.
[3] P. Poole‐Wilson,et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. , 2000, European heart journal.
[4] P. Poole‐Wilson,et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. , 2000, Circulation.
[5] D. Hall. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. , 2000, Journal of the American College of Cardiology.
[6] Salim Yusuf,et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.
[7] S G Thompson,et al. Survival of patients with a new diagnosis of heart failure: a population based study , 2000, Heart.
[8] J. Le Heuzey,et al. Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. , 2000, American heart journal.
[9] J. Cleland,et al. Is the prognosis of heart failure improving? , 2000, European journal of heart failure.
[10] M. Lauer,et al. Ventilatory and heart rate responses to exercise : better predictors of heart failure mortality than peak oxygen consumption. , 1999, Circulation.
[11] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[12] J. Cleland,et al. The LIDO, HOPE, MOXCON and WASH studies , 1999 .
[13] Y. Rosenberg,et al. In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators. , 1999, Journal of the American College of Cardiology.
[14] G. Pontone,et al. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. , 1999, American heart journal.
[15] U. Goldbourt,et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. , 1999, Journal of the American College of Cardiology.
[16] J. Cleland,et al. Sudden death in heart failure: vascular or electrical? , 1999, European journal of heart failure.
[17] K. Song,et al. Interaction of ACE Inhibitors and Aspirin in Patients with Congestive Heart Failure , 1999, The Annals of pharmacotherapy.
[18] P. Poole‐Wilson,et al. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study , 1999, European journal of heart failure.
[19] M. Komajda,et al. Risk stratification in chronic heart failure. , 1998, European heart journal.
[20] M. Gheorghiade,et al. Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. , 1997, Progress in cardiovascular diseases.
[21] S. Kayser. Clinical trials update. , 1997, Progress in cardiovascular nursing.
[22] A. Hall,et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. , 1997, European heart journal.
[23] A. Hall,et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. , 1996, European heart journal.
[24] David J. Weatherall,et al. Oxford textbook of medicine , 1996 .
[25] S. Nitter‐Hauge,et al. Risk Factors for Early and Late Mortality in Surgical Treatment of Coronary Artery Disease , 1995, Cardiovascular surgery.
[26] J. Cohn,et al. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. , 1995, Journal of cardiac failure.
[27] J P Klein,et al. Statistical methods for dependent competing risks , 1995, Lifetime data analysis.
[28] J. Cleland. The clinical course of heart failure and its modification by ACE inhibitors: insights from recent clinical trials. , 1994, European heart journal.
[29] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[30] Therapy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.
[31] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.
[32] G. Naccarelli,et al. A critical appraisal of the cardiac arrhythmia suppression trial (CAST). , 1991, Applied cardiopulmonary pathophysiology : ACP.